Search Results - "Mookerjee, B."

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Get full text

Gevokizumab, an interleukin-1β (IL-1β) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): “first-in-cancer” phase Ib study by Van Cutsem, E., Shitara, K., Deng, W., Vaury, A., Tseng, L., Wang, X., Millholland, J., Shilkrut, M., Mookerjee, B., Jonasch, E.

Get full text

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) by Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E., Li, D., Tafuto, S., Raj, N., Campana, D., Hijioka, S., Raderer, M., Guimbaud, R., Gajate, P., Pusceddu, S., Reising, A., Degtyarev, E., Mookerjee, B., Aimone, P., Singh, S.

Get full text

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma by Ascierto, P.A., Ferrucci, P.F., Stephens, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G.V., Di Giacomo, A.M., Svane, I., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B.P., Ghori, R., Ibrahim, N., Homet Moreno, B., Ribas, A.

Get full text

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC) by Keam, B., Kreitman, R.J., Wainberg, Z.A., Cabanillas, M.E., Cho, D.C., Italiano, A., Stein, A., Cho, J.Y., Schellens, J.H.M., Wen, P.Y., Zielinski, C.C., Boran, A.D., Mookerjee, B., Burgess, P., Rangwala, F., Subbiah, V.

Get full text

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial by Dummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V.G., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M.S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J.M., Long, G.V.

Get full text

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial by Atkinson, V.G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M.S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J.M., Long, G.V.

Get full text

3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM) by Grob, J.J, Amonkar, M, Karaszewska, B, Schachter, J, Dummer, R, Mackiewicz, A, Stroiakovski, D, Drucis, K, Grange, F, Chiarion-Sileni, V, Rutkowski, P, Lichinitser, M, Levchenko, E, Wolter, P, Hauschild, A, Long, G.V, Sun, P, McDowell, D.O, Mookerjee, B, Robert, C

Get full text

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma by Robert, C, Karaszewska, B, Schachter, J, Rutkowski, P, Mackiewicz, A, Stroyakovskiy, D, Lichinitser, M, Dummer, R, Grange, F, Mortier, L, Chiarion-Sileni, V, Drucis, K, Krajsova, I, Hauschild, A, Mookerjee, B, Legos, J, Schadendorf, D

Get full text

Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients by HAHN, T, RONDEAU, C, CZUCZMAN, M. S, SLACK, J, WETZLER, M, MOOKERJEE, B. K, SILVA, J, MCCARTHY, P. L, SHAUKAT, A, JUPUDY, V, MILLER, A, ALAM, A. R, BAER, M. R, BAMBACH, B, BERNSTEIN, Z, CHANAN-KHAN, A. A

“…We examined the incidence, risk factors and associated mortality of acute renal failure requiring dialysis (Renal Bearman Grade [BG] 3) in a 3-year cohort of…”
Get full text

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus by MOOKERJEE, B, ALTOMONTE, V, VOGELSANG, G

“…Chronic graft-versus-host disease (GVHD) is a common late complication of allogeneic bone marrow transplantation (BMT) and is the principal cause of morbidity…”
Get full text

Human herpes virus-6 encephalitis after bone marrow transplantation : successful treatment with ganciclovir by MOOKERJEE, B. P, VOGELSANG, G

“…Here we report a case that presented with sudden onset of neurological symptoms and was treated with ganciclovir. Polymerase chain reaction analysis for human…”
Get full text

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma by Long, Georgina V, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Schadendorf, Dirk, Lesimple, Thierry, Plummer, Ruth, Ji, Ran, Zhang, Pingkuan, Mookerjee, Bijoyesh, Legos, Jeff, Kefford, Richard, Dummer, Reinhard, Kirkwood, John M

“…In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%…”
Get full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial by Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD

“…Summary Background Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with…”
Get full text

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy by RAPOPORT, A. P, MEISENBERG, B, KENNEDY, A, JACOBS, M, HUDES, R, RUEHLE, K, SMITH, R, KIGHT, L, CHAMBERS, S, MACFADDEN, M, COTTLER-FOX, M, CHEN, T, SARKODEE-ADOO, C, PHILLIPS, G, TRICOT, G, FASSAS, A, FRANKEL, S. R, MOOKERJEE, B, TAKEBE, N, FENTON, R, HEYMAN, M, BADROS, A

“…Disease relapse occurs in 50% or more of patients who are autografted for relapsed or refractory lymphoma (NHL) or Hodgkin's disease (HD). The administration…”
Get full text

1242 Cediranib in combination with mFOLFOX6: results from the cohort expansion phase of a two-part Phase I study by LoRusso, P, Zalupski, M, Desai, S, Burris, H.A, Stella, P.J, Xu, J, Liu, Q, Mookerjee, B, Shields, A.F

Get full text

Activity of single-agent melphalan 220-300 mg m with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma

Get full text

Interferon‐α‐associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy by Shah, Manisha, Jenis, Edwin H., Mookerjee, Basab K., Schriber, Jeffrey R., Baer, Maria R., Herzig, Geoffrey P., Wetzler, Meir

“…BACKGROUND Acute renal failure, with or without massive proteinuria, is a rare idiosyncratic toxicity of interferon (IFN)‐α therapy. The authors sought to…”
Get full text

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC) by Mulders, P, Hawkins, R, Nathan, P, de Jong, I, Osanto, S, Porfiri, E, Protheroe, A, Mookerjee, B, Pike, L, Gore, M.E

Get full text